Edition:
United States

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

42.05USD
22 Jun 2018
Change (% chg)

$0.70 (+1.69%)
Prev Close
$41.35
Open
$41.55
Day's High
$42.05
Day's Low
$40.10
Volume
1,290,776
Avg. Vol
244,725
52-wk High
$68.05
52-wk Low
$24.05

Latest Key Developments (Source: Significant Developments)

Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock
Thursday, 8 Mar 2018 10:00pm EST 

March 8 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC-‍PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 4.0 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $54.00 PER SHARE​.  Full Article

Global Blood Therapeutics Announces Proposed Public Offering
Thursday, 8 Mar 2018 04:01pm EST 

March 8 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 3.50 MILLION COMMON SHARES.  Full Article

Global Blood Therapeutics Q4 Loss Per Share $0.94
Tuesday, 27 Feb 2018 04:07pm EST 

Feb 27 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.94.  Full Article

GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease
Tuesday, 9 Jan 2018 08:00am EST 

Jan 9 (Reuters) - Global Blood Therapeutics Inc ::GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD).  Full Article

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering
Friday, 15 Dec 2017 09:03am EST 

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares
Thursday, 14 Dec 2017 04:00pm EST 

Dec 14 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - ANNOUNCED AN AGREEMENT TO SELL $100.0 MILLION IN SHARES OF ITS COMMON STOCK.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE.  Full Article

Global Blood Therapeutics posts Q3 loss per share $0.66
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results.Q3 loss per share $0.66.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Global Blood Therapeutics - continue to expect cash,cash equivalents,marketable securities to be enough to take co to top-line data in hope study​.Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016​.  Full Article

Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440
Tuesday, 24 Oct 2017 08:00am EDT 

Oct 24 (Reuters) - Global Blood Therapeutics Inc ::Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440.Global Blood Therapeutics Inc - ‍world Health Organization has approved "voxelotor" as international nonproprietary name for gbt440​.  Full Article

Global Blood Therapeutics announces discontinuation of IPF program
Monday, 23 Oct 2017 07:00am EDT 

Oct 23 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics announces discontinuation of Idiopathic Pulmonary Fibrosis (IPF) program​.Says discontinuation of its GBT440 program for treatment of idiopathic pulmonary fibrosis​.Says ‍decision to discontinue is based on results from 3 proof-of-concept studies including phase 1 study in healthy volunteers.Says ‍decision to discontinue is also based on two phase 2A studies in patients with ipf called GBT440-006 and Zephyr​.Says data from proof-of-concept studies did not demonstrate sufficient overall clinical benefit to justify continuing IPF program.Says ‍remain on track to announce top-line clinical trial results from phase 3 Hope study in H1 2019 ​.Says ‍GBT440 was generally well tolerated across all three studies​.  Full Article

Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood Therapeutics
Tuesday, 3 Oct 2017 04:14pm EDT 

Oct 3 (Reuters) - Global Blood Therapeutics Inc :Point72 Asset Management LP reports 5.2 percent passive stake in Global Blood Therapeutics Inc ‍​as of October 2 - SEC filing.  Full Article

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS